Ridinilazole

DRUG3 trials

Sponsors

Summit Therapeutics

Conditions

Clostridioides Difficile InfectionClostridium Difficile Infection

Phase 2

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

CompletedNCT02784002

Summit TherapeuticsClostridium Difficile Infection

Start: 2014-12-31End: 2016-08-31Updated: 2017-10-12

Phase 3

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

CompletedNCT03595553

Summit TherapeuticsClostridioides Difficile Infection

Start: 2019-01-28End: 2021-11-17Updated: 2023-03-03

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

TerminatedNCT04802837

Summit TherapeuticsClostridioides Difficile Infection

Start: 2021-05-19End: 2022-09-28Updated: 2023-08-21

Related Papers

A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of <i>Clostridioides difficile</i> Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response

Clinical Infectious Diseases2024-02-0227 citations

Ridinilazole for the treatment of Clostridioides difficile infection.

2019-02-268 citations